1. Home
  2. VS vs MYNZ Comparison

VS vs MYNZ Comparison

Compare VS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

HOLD

Current Price

$1.19

Market Cap

6.4M

Sector

Technology

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.03

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VS
MYNZ
Founded
2013
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VS
MYNZ
Price
$1.19
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
87.7K
305.7K
Earning Date
11-14-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,179,348.00
$659,935.00
Revenue This Year
$3,459.21
N/A
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
2281.70
N/A
52 Week Low
$1.15
$0.92
52 Week High
$3.79
$8.20

Technical Indicators

Market Signals
Indicator
VS
MYNZ
Relative Strength Index (RSI) 32.94 37.14
Support Level $1.20 $1.00
Resistance Level $1.47 $1.15
Average True Range (ATR) 0.10 0.08
MACD 0.00 0.01
Stochastic Oscillator 18.41 37.04

Price Performance

Historical Comparison
VS
MYNZ

About VS Versus Systems Inc.

Versus Systems Inc offers a suite of proprietary business-to-business software tools that are meant to drive user engagement through gamification and rewards. These tools allow its partners to offer in-game prizes and rewards, including merchandise, coupons, digital goods, and sweepstakes entries - inside their websites, their venues, or their streaming media content. Its customers are mostly sports teams, venues, and advertising agencies, which typically use its products as part of their live events or as part of an advertising campaign with the goal of engaging fans, increasing consented first-party data, and increasing sales. The company operates in Canada and the USA.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: